Cost-effectiveness of oral nirmatrelvir/ritonavir in patients at high risk for progression to severe COVID-19 in the United States
Description
CONCLUSIONS: NMV/r is cost-effective vs best supportive care for patients at high-risk for severe COVID-19 from a US health sector perspective.
